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Abstract
Anti-angiogenic treatment of glioblastoma with Vascular Endothelial Growth Factor (VEGF)- or VEGF Receptor 2 (VEGFR2)
inhibitors normalizes tumor vessels, resulting in a profound radiologic response and improved quality of life. This approach
however does not halt tumor progression by diffuse infiltration, as this phenotype is less angiogenesis dependent.
Combined inhibition of angiogenesis and diffuse infiltrative growth would therefore be a more effective treatment
approach in these tumors. The HGF/c-MET axis is important in both angiogenesis and cell migration in several tumor types
including glioma. We therefore analyzed the effects of the c-MET- and VEGFR2 tyrosine kinase inhibitor cabozantinib (XL184,
Exelixis) on c-MET positive orthotopic E98 glioblastoma xenografts, which routinely present with angiogenesis-dependent
areas of tumor growth, as well as diffuse infiltrative growth. In in vitro cultures of E98 cells, cabozantinib effectively inhibited
c-MET phosphorylation, concomitant with inhibitory effects on AKT and ERK1/2 phosphorylation, and cell proliferation and
migration. VEGFR2 activation in endothelial cells was also effectively inhibited in vitro. Treatment of BALB/c nu/nu mice
carrying orthotopic E98 xenografts resulted in a significant increase in overall survival. Cabozantinib effectively inhibited
angiogenesis, resulting in increased hypoxia in angiogenesis-dependent tumor areas, and induced vessel normalization. Yet,
tumors ultimately escaped cabozantinib therapy by diffuse infiltrative outgrowth via vessel co-option. Of importance, in
contrast to the results from in vitro experiments, in vivo blockade of c-MET activation was incomplete, possibly due to
multiple factors including restoration of the blood-brain barrier resulting from cabozantinib-induced VEGFR2 inhibition. In
conclusion, cabozantinib is a promising therapy for c-MET positive glioma, but improving delivery of the drug to the tumor
and/or the surrounding tissue may be needed for full activity.
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Introduction
Glioblastoma is a highly aggressive primary brain tumor that is
characterized by extensive areas in which tumor cells diffusely
infiltrate the brain parenchyma. A well-known hallmark of this
cancer type is the presence of a necrotic core, surrounded by a rim
in which hypoxia-induced neovascularization occurs [1]. Angio-
genesis in these areas is associated with vessel leakiness, which
contributes to edema and high intracranial pressure, aggravating
symptoms that by themselves can be lethal. Local vessel leakage is
exploited to diagnose glioblastoma, as it results in extravasation of
intravenously administered contrast agents like Gd-DTPA which
can be readily visualized by MRI. Glioblastomas are generally
operated upon to the maximum feasible extent, followed by
radiotherapy and chemotherapy with temozolomide. Remnants of
diffusely growing tumor cells will however inevitably result in
tumor recurrence and median survival is currently still only 14.6
months [2].
It is well recognized now that inhibition of VEGF-A signaling
pathways in neovascular endothelial cells, either by the neutral-
izing antibody bevacizumab or selective VEGFR2 tyrosine kinase
inhibitors, induces a radiological response, significantly reduces
edema and may substantially improve quality of life [3–6].
Bevacizumab is now approved by the FDA for treatment of
recurrent glioma. However, it has also become clear from a
number of preclinical but also clinical studies that the diffuse
infiltrative phenotype of glioblastomas is not sensitive to angio-
genesis inhibition [5,7–9]. We previously showed that different
anti-angiogenic treatments of orthotopic E98 xenografts (display-
ing both angiogenesis and diffuse infiltration [10]) affect only the
angiogenic tumor component [8,9,11]. Apparently, anti-angio-
genic therapies drive tumor cells to adapt a resistant, angiogenesis-
independent phenotype in which tumor cells obtain their blood
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supply entirely from pre-existent vasculature [12–16]. These
therapies have even been suggested to increase tumor cell invasion
in glioma and other tumor types [17,18] and this appears to be
associated with induction of hypoxia [19]. It is therefore of major
importance for effective glioma treatment that approaches become
available that tackle diffuse infiltrative tumor growth.
The c-MET tyrosine kinase receptor has been linked to both
tumor angiogenesis and the invasive phenotype of glial and other
tumors [19,20]. Upon binding of its ligand hepatocyte growth
factor (HGF, scatter factor), c-MET is phosphorylated on tyrosine
residues Y1234/1235 (kinase domain) and Y1349 and Y1356, the
latter two residues with their surrounding amino acids functioning
as docking sites for substrates such as Gab1, Grb2 and
phosphatidylinositol 3 kinase (PI3K) [21,22]. Downstream signal-
ling of c-MET involves important pathways including RAS/PI3K
and ERK/MAPK, which are associated with tumorigenesis and
cancer progression [23].
Amplification of the c-MET gene (located on chromosome 7) is
seen in glioblastomas [24] and both c-MET and HGF are
frequently overexpressed in glioma specimens and cell lines. HGF
is a strong stimulator of in vitro glioma cell migration [25–27] and
c-MET expression has also been demonstrated in invasive glioma
cells [25]. Simultaneous targeting of the VEGF and c-MET
pathways may therefore be an interesting therapeutic approach for
c-MET-positive glioblastoma because it will reduce vessel leakage
(resulting in edema reduction) and simultaneously may reduce
tumor cell migration and thus tumor progression. Cabozantinib
(XL-184, Exelixis, South San Francisco, CA) is a small compound
tyrosine kinase inhibitor of VEGFR2, c-MET and RET and has
been shown to block tumor development in the RipTAG2 mouse
model of pancreatic carcinogenesis more effectively than blockade
of c-MET or VEGFR2 alone [19,28,29]. Cabozantinib was
recently FDA-approved for treatment of medullary thyroid cancer.
The aim of the current work was therefore to test the effects of
cabozantinib in mice carrying highly aggressive orthotopic E98
glioma xenografts [10]. We show that cabozantinib blocks vascular
leakage in this c-MET positive tumor model and gives a significant
survival benefit which was not observed in previous experiments
from our lab with bevacizumab or other VEGFR2 inhibitors [8,9].
Interestingly, whereas cabozantinib completely blocked c-MET
tyrosine phosphorylation in vitro in E98 cell cultures, phosphory-
lated c-MET was still present in remaining diffuse infiltrative
tumor areas in treated mice. We propose that the anti-VEGFR2
activity of cabozantinib results in a restoration of the blood-brain
barrier, thereby precluding an efficient distribution of the
compound to the tumor cells and reducing c-MET inhibitory
activity.
Materials and Methods
Cell Culture
E98NT cells (cell line derived from E98 xenografts, described in
[30]) were cultured in DMEM supplemented with 10% FCS and
pen/strep in the presence of 5% CO2 at 37uC. HUVECs were
cultured in EBM medium, supplemented with FCS, bFGF and
VEGF (Lonza) according to the manufacturer’s instructions.
Protein Expression Analysis
E98NT cells or HUVECs were plated in 6 well dishes in
appropriate media at a density of 56105 cells per well. The
following day cabozantinib (0, 0.01, 0.1, 0.5, 1 and 10 mM in
DMSO) was added. After a 30 min incubation, cells were washed
with ice-cold PBS and protein extracts were generated using RIPA
buffer supplemented with protease and phosphatase inhibitors
(Roche Applied Science). Similarly, extracts were generated from
E98NT cells treated for 24 h with 1 and 10 mM cabozantinib (for
assaying apoptosis) and sections of snap frozen xenograft brains
(approximately 20 mg of tissue). Protein lysates were cleared by
centrifugation and protein concentrations were measured using
the BCA Protein Assay Kit (Thermo Scientific) according to
manufacturer’s instructions. Proteins (20–40 mg/lane) were sub-
jected to SDS-PAGE and Western Blotting using antibodies
directed against c-MET (clone EP1454Y, Epitomics and clone
D1C2, Cell Signaling Technology (CST)), phospho-c-MET
(Y1234/1235, clone D26, CST), phospho-AKT (S473, clone
D9E, CST) phospho-ERK1/2 (Thr202/Tyr204, clone 20G11,
CST), anti-U1-70 (to detect apoptosis, [31]) and a-tubulin (clone
236-10501, Molecular Probes) or c-tubulin (clone C20, goat,
Santa Cruz Biotechnology) as internal control. Antibodies were
detected using appropriate secondary antibodies, labeled with
IRDye700 or IRDye800 infrared dyes. Signals were visualized and
quantified when appropriate, using the Odyssey Infrared Imaging
System (LI-COR Biosciences Odyssey Application Software
version 3.0.30).
Dose Response Analysis
IC50 of cabozantinib was determined as follows: cells were
plated at a concentration of 26104 cells per well in 96-wells plates.
The next day increasing concentrations of cabozantinib (in
DMSO) were added to the medium. Each condition was tested
in quadruplicate in at least three independent experiments.
Metabolic activity of the cells was determined 4 days following
start of TKI treatment by incubation with 0.5 mg/ml MTT in
PBS (Sigma-Aldrich, St. Louis, MO). After a 3.5 hr incubation at
37uC formazan crystals were dissolved in MTT solvent (0.1%
NP40 and 3.4 mM HCl in isopropanol) and optical densities were
measured at 560 nm. IC50 concentrations were determined using
sigmoidal dose-response (variable slope) statistics and normalized
in GraphPad Prism.
Cell Migration Assays
E98 spheroids were generated by the hanging drop method. In
brief, 0.7 ml methylcellulose (Sigma M6385, final concentration
1.68 mg/ml) was added to 4.3 ml E98 cell suspension in normal
culture medium (500,000 cells total) and drops of 25 ml containing
approximately 2,500 E98 cells were seeded in a dry culture dish.
The dish was then inverted and incubated overnight at 37uC in the
presence of 5% CO2. The next day, individual spheroids were
seeded in a matrigel-coated 96-well imaging culture dish (Matrigel:
BD cat 356237, 96-well plates: BD falcon imaging plates cat
353219) and grown further at 37uC and 5% CO2. Individual
spheroids were photographed at t = 0 h in a culture system which
allows for live cell imaging, after which they were incubated with
0, 1 or 10 mM cabozantinib. After 24 h, wells were washed with
PBS and cells were fixed with 4% PFA in 0.1 M phosphate buffer,
followed by DAPI staining. Fluorescent and phase-contrast images
were then taken and Image J software was used to quantify
spheroid outgrowth. Briefly, cells which had migrated from the
spheroids were selected automatically using a cell mask. Numbers
of cells that had migrated out of the spheroids (n = at least 32 for
each condition) were measured. Statistical analyses involved
ANOVA and post-hoc Tukey’s Multiple Comparison Test.
Animals
Athymic female BALB/c nu/nu mice (18–25 gram, age 6–8
weeks) were kept under specified pathogen free conditions and
received food and water ad libitum. The local Animal Experimental
Committee of the Radboud University Nijmegen Medical Center
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approved all experiments. E98 glioblastoma cells derived from
subcutaneous xenograft tumors were injected intracranially under
isoflurane anesthesia as described previously [10]. All efforts were
made to minimize suffering. Animals were closely monitored by
visual inspection and weighed daily from start of treatment (see
below) and sacrificed when evident signs of tumor burden
(especially weight loss .20%, severe neurological dysfunction)
were observed. Brain, liver and kidneys were harvested, and parts
were formalin fixed and paraffin embedded or snap-frozen in
liquid nitrogen for further analysis.
Therapy
Animals carrying E98 tumors were randomly divided into
placebo and cabozantinib treatment groups. Treatment was
started at day 12, when signs of tumor growth became apparent,
as evidenced by the presence of edema in T2 weighted MR
imaging. Water-suspended cabozantinib (XL184, Exelixis, South
San Francisco) was given daily by oral gavage in doses of either
60 mg/kg (n= 3) or 100 mg/kg (n= 10) in a volume of 100 ml. A
control group (n= 10) received water daily by oral gavage.
Immunohistochemistry (IHC)
Immunohistochemical stainings were performed as described
before [9]. In short, after epitope retrieval by boiling in citrate
buffer (pH 6.0), 4 mm tissue sections were incubated with primary
antibodies against GLUT1 (Neomarkers), CD34 (clone MEC14.7,
Hycult biotech), c-MET (clone EP1454Y, Epitomics), phospho-c-
MET (Y1234/1235, clone D26, CST), MCT4 (clone H90, Santa
Cruz), cleaved caspase 3A (clone C92-605, BD Pharmingen) and
Ki-67 (clone Sp6, Thermo Fisher Scientific). Appropriate
biotinylated secondary antibodies were used for detection using
the Avidine Biotine Complex (ABC) method (Vector Laborato-
ries). Specific signals were visualized by staining with 3-amino-9-
ethyl-carbazole (AEC, Scytek Laboratories) or 3,39-diaminoben-
zidine (Power-DAB, ImmunoLogic) solution. All sections were
counterstained with haematoxylin and mounted in Imsol Mount-
ing medium (Klinipath B.V.).
Image Analysis
Cell proliferation, hypoxia and vessel densities were quantified
using KS400 software (Carl Zeiss AG, Germany) with a custom-
written macro on images acquired on a Zeiss Axioskop II
microscope coupled to a CCD-RGB camera. For proliferation,
five random non-overlapping diffuse infiltrative or compact tumor
containing microscopic fields (magnification x200) were analyzed
per section. Compact and diffuse areas were recognized by gross
histology, with compact areas being present in the ventricles or
leptomeninges, and diffuse areas defined by the intermittent
presence of white matter tracts in H&E staining. The proliferative
fraction was defined as the number of proliferative cells (based on
Ki-67 positivity) divided by the total number of nuclei in a tumor
region. Ratios were determined and the average value for the
different fields per slide was used in further calculations.
For hypoxia quantification, compact tumor areas, defined as
sharply bordered regions lacking normal brain parenchyma in
between the tumor cells, and hypoxic regions (based on MCT4
positivity) were selected interactively. The hypoxic fraction was
defined as the total hypoxic area divided by the total tumor area.
Vessel densities were measured in GLUT-1 immunostainings
and counted in 5 high power fields per section in both compact
and diffuse areas. Since neovasculature in compact areas often lack
blood-brain barrier characteristics (e.g. GLUT-1 expression), also
CD34 stainings were performed.
Statistical comparisons were done by normality analysis,
followed by a Student’s t-test (two-sided) using GraphPad Prism
v4. For both control and 100 mg/kg cabozantinib treated brains,
n = 10. A p value of #0.05 was considered as statistically
significant.
Contrast-enhanced Magnetic Resonance Imaging
CE-MRI was performed in a 7T MR system (ClinScan, Bruker
BioSpin, Ettlingen, Germany) equipped with a clinical user
interface (syngo MR, Siemens, Erlangen, Germany). When
tumor-related symptoms became apparent, animals were anesthe-
tized using 1–2% isourane in a 70% N2O and 30% O2 mixture
and placed in a prone position in an MR cradle. Breathing was
monitored throughout the MR experiment and the animals’ core
temperature was maintained at 37.5uC using a continuous flow of
warm air (SA Instruments, Inc., Sunny Brook, NY, USA).
Anatomical references were acquired using a multi-slice localizer
with slices in the three main orthogonal directions. A turbo spin
echo sequence with following settings were used: repetition time
(TR) 3880 ms, echo time (TE) 43 ms and a turbo factor of 7. The
scans had a resolution of 98 mm in-plane and a thickness of
0.7 mm per slice. A bolus of 0.2 ml of Gd-DTPA (20 mM,
MagnevistH, Schering, Germany) was injected intravenously via a
pre-inserted tail vein catheter and additional sets of T1-weighted
images were acquired 2–3 minutes after injection.
Results
Elevated expression of c-MET in glioma specimens has been
documented by several groups. Whereas up to 35% of primary
gliomas overexpress this RTK, this percentage increases to up to
75% in recurrent glioblastomas [32]. Often, heterogeneity in c-
MET expression is found between tumor cells [33] and some
papers have reported on the expression of c-MET on endothelial
cells too [34]. This is especially interesting since multi-targeted
tyrosine kinase inhibitors such as cabozantinib have been
developed that have specificity against both VEGFR2 and c-MET.
In the past we have established a number of glioblastoma
xenograft lines by either subcutaneous or direct intracerebral
implantation of surgically derived tumor cell suspensions in
immunodeficient mice, which are subsequently maintained by
serial transplantation [10]. One xenograft line that has been
extensively analyzed for its response to anti-angiogenic treatment
is E98. This line routinely presents with diffuse tumor growth in
the brain parenchyma, using co-opted blood vessels and white
matter tracts as scaffold. The presence of additional areas of
angiogenesis-dependent growth makes this model of high trans-
lational relevance for testing of targeted therapies. Western blot
analysis using c-MET and phospho-c-MET specific antibodies
(recognizing the phospho-tyrosines Y1234 and Y1235) revealed
that only E98 xenografts express significant amounts of the
activated receptor, consistent with our observation that chromo-
some 7 is amplified in this xenograft line (Figure 1A and [10]).
IHC analysis confirmed c-MET expression in E98, showing
expression in all tumor cells (note that the non-stained structures in
Figure 1D correspond to white matter tracts, as is clear from H&E
staining of the serial section in Figure 1B). IHC using the phospho-
specific anti-c-MET antibody also confirmed the presence of
activated c-MET, although in a heterogeneous fashion, being
present predominantly in diffuse infiltrating tumor cells in the
corpus callosum and adjacent white matter (Figure 1E, arrow and
1F). Furthermore, activated c-MET was detected in a rim of non-
infiltrative tumor cells (routinely present in this model in the
leptominges and ventricles) at the interface with normal brain
Dual Targeting of Tumor Cells and Stroma in Glioma
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parenchyma (inset in Figure 1E and not shown). In central regions
of compact growing tumor areas c-MET was not activated
(arrowhead in Figure 1E).
We reasoned that the partially angiogenic character of the E98
xenograft model, in combination with high c-MET expression and
activation in diffuse infiltrative areas makes this model highly
relevant to study simultaneous inhibition of VEGFR2 and c-MET
signaling. First, we investigated whether cabozantinib therapy
blocked c-MET activation in vitro. Treatment of the E98NT cell
line, derived from the E98 xenograft model [30] resulted in an
efficient and dose-dependent inhibition of c-MET phosphorylation
after 30 minutes (Figure 2A). Downstream signaling via AKT was
also significantly inhibited by cabozantinib (note the ,82%
reduction of phosphorylated AKT and the accompanying
decrease in phosphorylated ERK1/2 at concentrations higher
than 0.5 mM). Consistently, cabozantinib caused a dose-dependent
inhibition of proliferation in E98NT cells (Figure 2B, IC50 ,
89 nM). Cabozantinib did not induce apoptosis in vitro as
demonstrated by Western blot staining with anti-U1-70 antibody
(Figure 2F). In an in vitro spheroid-based cell migration assay, we
Figure 1. c-MET is activated in E98 xenografts. Panel A shows a Western blot containing protein extracts of different xenografts as indicated
(40 mg/lane) and stained with a pan and an Y1234/1235 phosphorylated (P-) c-MET specific antibody. As a loading control, c-tubulin was included.
Immunohistochemical analysis reveals prominent c-MET expression and activation in orthotopic E98 xenografts (C–F). Gross appearances of an E98
tumor are shown in C and E, while D and F show magnifications of the boxed areas in C and E. The H&E section in B illustrates the diffuse nature of
these tumors, arrows pointing at white matter tracts and comparison with D shows homogeneous expression of c-MET by tumor cells. Arrow in E
points at diffuse infiltrative tumor cells in white matter with activated c-MET, while the arrowhead points at a more compact paraventricular tumor
area. The inset in E represents an area with compact leptomeningeal growth partly positive for activated c-MET. The pictures shown are
representative for this xenograft model. Size bars: B, D, F 200 mm; C 1 mm and E 500 mm.
doi:10.1371/journal.pone.0058262.g001
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observed that cabozantinib significantly reduced the number of
E98 cells that are able to migrate away from the spheroids
(Figure 2C–D, p,0.001, Post-hoc Tukey’s Multiple Comparison
Test). Thus, c-MET signals have bearing for E98 tumor cell
migratory potential as well. These inhibitory effects can be
attributed to c-MET inhibition since E98 cells do not express
VEGFR2 (Figure 2E). The inhibitory activity of cabozantinib on
VEGFR2 [28] was confirmed on cultures of HUVECs and was
complete at concentrations of 10 mM (Figure 2E).
We next subjected mice carrying established orthotopic E98
xenografts, as determined by visibility of edema on T2-weighted
MR imaging (see Figure 3A for an example) to treatment with
cabozantinib. An initial pilot experiment with 60 mg/kg cabo-
zantinib (n = 3) resulted in a full radiologic response using Gd-
DTPA enhanced MRI, similar to our previous observations with
bevacizumab, vandetanib and sunitinib [7–9]. However, large
invasive tumors with hypoxic compact regions (identified by
MCT4 expression) remained present after treatment while no
signs of hypoxia were seen in the diffuse tumor areas (not shown).
There was a non-significant trend towards increased survival
(mean survival of 19 days in control vs. 23 days in 60 mg/kg
cabozantinib treated animals). A larger group of animals (n = 10)
was therefore treated with 100 mg/kg cabozantinib, which did
result in significantly prolonged survival compared to control-
treated mice (median survival of tumor-bearing control mice was
20 days vs. 32 days for the 100 mg/kg cabozantinib group, log
Figure 2. In vitro effects of Cabozantinib on c-MET and VEGFR2 signaling. Panel A shows a Western blot of E98NT cell extracts (20 mg per
lane) treated for 30 minutes with different concentrations of cabozantinib as indicated. Protein extracts were analyzed for c-MET, phospho-c-MET,
AKT, and ERK1/2, using a-tubulin as a loading control. B) MTT assays were done to determine the IC50 concentration of cabozantinib on E98NT cells.
Experiments were performed at least in triplicate. C) Effects of cabozantinib on cell migration. Shown are representative examples of DAPI-stained
spheroids after 24 hr incubation with indicated concentrations. Number of outgrowing and migrating cells per spheroid are shown in panel D (***:
p,0.001). Number of migrating cells were significantly different between groups (one-way ANOVA, p,0.0001). Post-hoc Tukey’s Multiple
Comparison Test revealed significant differences groups as indicated (***: p,0.001). E) Western blot of cell lysates of E98NT and HUVEC extracts,
treated with 10 ng/ml VEGF with or without cabozantinib, and stained for VEGFR2, phospho-VEGFR2 and a-tubulin as an internal control. Note the
absence of VEGFR2 in E98NT cells. F) Western blot of treated E98NT cell extracts with the anti-apoptotic antibody U1-70. Control sample consists of
Jurkat cells treated with anisomycin.
doi:10.1371/journal.pone.0058262.g002
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rank test p,0.0001, Figure 3B). All further experiments refer to
this group. Prior to sacrifice, mice were subjected to Gd-DTPA-
enhanced MRI. Treatment with 100 mg/kg cabozantinib result-
ed, as expected, again in a complete absence of contrast
enhancement (Figure 3C, lower panels) despite clear presence of
extensive tumor (H&E staining in figure 3D, note that these
sections correspond to the MR scans). Upon 100 mg/kg
cabozantinib treatment, tumors generally had converted to a
mainly diffuse infiltrative phenotype (see figure 3D, lower panels)
similar to our previous findings with vandetanib and sunitinib
[8,9]. In all animals limited areas of compact tumor were present
to varying extent and these areas were significantly more hypoxic
than in control animals (p = 0.003, see IHC for hypoxia induced
monocarboxylate transporter-4 (MCT4, Figure 4A–C) confirming
previous observations with other angiogenesis inhibitors [9].
Staining for GLUT-1, another marker for hypoxia, gave similar
results (not shown).
Diffuse infiltrative tumor regions did not show signs of hypoxia
in control and treated tumors and based on caspase stainings
apoptotic cells were very infrequent, also in treated tumors (not
shown). Both compact and more invasive tumor areas were
analyzed for proliferation differences, based on Ki-67 positivity in
IHC. The proliferative fraction did not differ between controls and
treated tumors in diffuse infiltrative regions, but proliferation was
significantly less in compact tumor regions after treatment
(p = 0.04, Figure 4D–F).
GLUT-1 is, except for hypoxic cells, also expressed on brain
capillaries and can be utilized as a blood vessel marker in the CNS.
Tumor vessel densities were quantified and did not differ in diffuse
areas between treatment and placebo groups (Figure 4G–I). Vessel
densities in compact areas were difficult to quantify based on
GLUT-1 staining because neovasculature often does not express
this differentiation marker. Based on CD34 stainings (a marker of
activated (neo)vasculature), vessel densities appeared lower in
cabozantinib treated animals (compare Figure 4J and K), but as
this treatment may also result in a downregulation of CD34
expression on vessels, these data are difficult to interpret in terms
of vascular densities. It is important to realize that our studies were
not time-matched, making it impossible to compare tumor
volumes in treated and control animals.
To investigate whether the remaining diffuse infiltrative tumor
might be the result of incomplete c-MET inhibition, we prepared
tumor extracts from treated and control animal brains and
prepared Western blots. As opposed to our in vitro data, even
dosing as high as 100 mg/kg cabozantinib (resulting in plasma
levels of 30 mM [29]) was not able to fully prevent c-MET
phosphorylation (Figure 4L) and this finding was confirmed with
IHC for phospho-c-MET (Y1234/1235, Figure 4M).
Discussion
The proposed functional role of c-MET in tumor cell migration
makes this receptor an attractive therapeutic target in c-MET
positive glioblastoma. The high expression and activation levels of
c-MET in diffuse E98 tumor areas supports the notion that c-
MET is actively involved in tumor cell migration [20]. Targeting
of c-MET may further be beneficial as signaling from this receptor
may induce and maintain the glioblastoma stem cell-like
phenotype and therefore resistance to chemotherapy and radio-
therapy [35].
Cabozantinib treatment of in vitro cultures of E98 cells greatly
reduced phosphorylation of AKT and ERK. This was accompa-
nied by a 50% inhibition of cell growth at concentrations as low as
89 nM, which is consistent with the involvement of these signal
transducers in PI3K and MAPK signaling. In vitro migration assays
showed potent effects of cabozantinib on single cell migration,
further strengthening a role of c-MET in cell migration as well.
E98 tumors became largely invisible in CE-MRI under
cabozantinib therapy, and similar phenomena have been observed
in clinical studies, with a radiological response as early as one day
after start of therapy [36]. This effect of vascular normalization,
rendering capillaries in brain tumors impermeable to MR contrast
agents by restoring the blood-brain barrier, is a well known
phenomenon which is the result of VEGFR2 inhibition [7,15,37].
A reduced vessel density in compact tumor areas in cabozantinib
treated mice may also have contributed to some extent to the
reduced visibility in CE-MRI. The persistent presence of MRI-
invisible tumor confirms our earlier finding that the high blood
vessel density in brain can accommodate tumor growth via vessel
cooption [14], i.e. without the necessity for neovascularization.
High dose cabozantinib treatment in our study resulted in a
significant improvement of survival. Kamoun et al. have shown
that anti-angiogenic treatment of mice carrying orthotopic glioma
may result in improved survival by a sole reduction of edema [38].
In previous experiments, we examined the effects of VEGFR2
inhibition by bevacizumab, vandetanib and sunitinib, alone or in
combination. Even combinations of these compounds did not
result in improved survival of E98-carrying mice, although there
seemed to be a complete blood-brain barrier restoration [9].
Therefore, it is likely that improved survival is the result of
additional c-MET targeting. Of note, a phase II trial of
cabozantinib for recurrent glioblastoma also revealed clinical
activity of this compound [36].
The high efficacy of cabozantinib to E98 cells in vitro contrasts
with our in vivo results. Although the increased survival was
unprecedented compared to previously used angiogenesis inhib-
itors, tumors could still escape therapy via diffuse growth. The
exact contribution of c-MET during tumor progression in E98
xenografts is somewhat difficult to assess. In a recent paper an
interesting explanation for increased invasiveness of glioblastoma
in response to VEGF inhibition has been proposed [20]. These
authors demonstrated that c-MET activation is inhibited in
glioblastoma cells that also express VEGFR2 in the presence of
VEGF. This was suggested to be the result of activation of the
VEGFR2-associated protein tyrosine phosphatase PTP1B, result-
ing in dephosphorylation of its target c-MET. According to this
hypothesis, inhibition of VEGF-A releases PTP1B from the multi-
receptor complex, unleashing c-MET and resulting in increased
diffuse infiltrative tumor growth. This might complicate the use of
compounds like cabozantinib, as it may bear antagonistic activities
in itself. However, it must be realized that this is only relevant for
glioblastomas that are positive for both c-MET and VEGFR2. As
E98 tumor cells do not express VEGFR2 this hypothesis is not
applicable to this model and other explanations must be found for
the escape from therapy.
One such alternative explanation comes from our finding that
cabozantinib plasma concentrations of approximately 30 mM
[29] did not entirely annihilate c-MET activation whereas
in vitro, concentrations as low as 0.5 mM sufficed to achieve
complete inhibition. Reduced penetration of the drug into the
tumor and surrounding tissue, as well as reduced free
concentrations of drug due to protein-binding in blood and
tissue, may account for the apparent reduction in potency.
Pharmacokinetic studies and measurement of steady-state levels
in brain would be appropriate.
The difference between the apparent in vitro and in vivo potency
of cabozantinib with respect to c-MET inhibition poses us with an
interesting dilemma. We demonstrated in a previous study that the
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combination of vandetanib and the DNA-alkylating agent
temozolomide was less effective than temozolomide alone [8].
This was attributed to vessel normalization and concomitant
‘restoration’ of the blood-brain barrier, resulting in a hampered
distribution of the chemotherapeutic agent to the tumor cells. To
what extent cabozantinib can pass the blood-brain barrier is not
exactly known. If passage would be inefficient, it may be
envisioned that a short period of cabozantinib treatment, enough
to restore the blood-brain barrier, will result in inhibition of
distribution of the compound to tumor cells in later stages of
treatment. According to this hypothesis, only during the initial
cabozantinib administrations, the compound will reach tumor cells
and have anti-migratory and anti-proliferative effects. In later
stages of tumor growth, tumor access may be limited by the
restored blood-brain barrier, although it is likely that this block is
not 100%, given that phospho-c-MET is still significantly reduced
in treated tumors. This may indeed explain the significant delay in
tumor growth that we observed. In this respect it would be very
worthwhile to investigate whether sequential targeting of c-MET
and VEGFR2 with monotargeted compounds would be more
effective. Such schemes may involve giving intermittent cycles of c-
MET inhibitor, followed by VEGFR2 inhibitors, which would
effectively result in locking up the c-MET inhibitors in the tumor
cell compartment. Such studies are underway in our lab.
Figure 3. Cabozantinib prolongs survival of mice bearing orthotopic E98- xenografts. Mice were treated with 100 mg/kg cabozantinib
from day 12 post tumor inoculation, when tumor was detected via abnormalities in T2 images (see panel A for a representative example). B) Survival
curves for placebo (n = 10) and cabozantinib (n = 10) treated animals. Note that, for ethical reasons, mice were sacrificed when excessive weight loss
and signs of neurological dysfunction occurred. Median survival was significantly different between the groups (20 and 32 days respectively, log rank
test, p,0.0001). C) Representative examples of T1-weighted MRI of control (upper row) and treated (lower row) E98 bearing animals before (pre) and
2–3 minutes after (post) Gd-DTPA injection. [Post-pre]/pre represents subtracted images. Note the complete loss of contrast enhancement in treated
animals. Panel D shows H&E staining of sections, corresponding to the slices shown in the MR images. Bars: overviews 2 mm, zoom 200 mm.
doi:10.1371/journal.pone.0058262.g003
Dual Targeting of Tumor Cells and Stroma in Glioma
PLOS ONE | www.plosone.org 7 March 2013 | Volume 8 | Issue 3 | e58262
Acknowledgments
We thank Dr. Dana Aftab from Exelixis Inc. for providing cabozantinib,
Dr. Peter Friedl and Pavlo Grytsenko for protocols and advice on the
spheroid migration assay, Ms Carla Onnekink for providing us with anti-
U1-70 antibody and Bob Hamans and Andor Veltien for technical
assistance with MR measurements. We thank Geert Poelen, Aglaja Zwiers,
Jeroen Mooren and Bianca Lemmers van de Weem for assistance with
animal experiments.
Author Contributions
Discussions and approval of manuscript: ACN AB PW AW WH KV JvdL
AH WPJL. Conceived and designed the experiments: ACN PW WPJL.
Performed the experiments: ACN AB AW KV WPJL. Analyzed the data:
ACN AB KV WH JvdL AH WPJL. Contributed reagents/materials/
analysis tools: AB WH AW AH WPJL. Wrote the paper: WPJL, ACN,
PW.
References
1. Wesseling P, Ruiter DJ, Burger PC (1997) Angiogenesis in brain tumors;
pathobiological and clinical aspects. J Neurooncol 32: 253–265.
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, et al. (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus
Figure 4. In vivo effects of cabozantinib treatment in E98 xenografts. Panels A and B show representative examples of IHC for the hypoxia
marker MCT4 in control and cabozantinib-treated tumor bearing animals. Hypoxia in compact tumor regions is significantly increased after treatment
(Students t-test, p = 0.003, panel C). D and E show examples of Ki67 stainings in compact tumor areas. Proliferation indices were significantly different
in these regions (Students t-test p = 0.04), but no difference was detected in diffuse tumor areas (panel F). Panels G and H show representative
examples of GLUT-1 vessel staining. Automated quantification revealed no differences between vessel densities of diffuse tumor areas in control vs
treated mice (I). Numbers of CD34-positive vessels were lower in cabozantinib treated mice (see panels J and K, arrows point at blood vessels), but
these data were not quantified because vessels without CD34 expression were also observed in these mice. L: Western blot analysis of protein
extracts (50 mg protein/lane), derived from cabozantinib-treated xenografts reveals a substantial, though not complete, reduction of c-MET
phosphorylation. As a loading control, c-tubulin was included. Immunohistochemistry for phospho-c-MET (Y1234/1235) also shows the presence of
phosphorylated c-MET in treated animals, as visualized in panel K. Size bars: A–B 2 mm, D–E 100 mm, G, H, J, K 200 mm,
doi:10.1371/journal.pone.0058262.g004
Dual Targeting of Tumor Cells and Stroma in Glioma
PLOS ONE | www.plosone.org 8 March 2013 | Volume 8 | Issue 3 | e58262
radiotherapy alone on survival in glioblastoma in a randomised phase III study:
5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459–466.
3. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, et al. (2009)
Bevacizumab alone and in combination with irinotecan in recurrent glioblas-
toma. J Clin Oncol 27: 4733–4740.
4. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, et al. (2007)
Angiogenesis in brain tumours. Nat Rev Neurosci 8: 610–622.
5. Verhoeff JJ, van Tellingen O, Claes A, Stalpers LJ, van Linde ME, et al. (2009)
Concerns about anti-angiogenic treatment in patients with glioblastoma
multiforme. BMC Cancer 9: 444.
6. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, et al.
(2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin
Oncol 25: 4722–4729.
7. Claes A, Gambarota G, Hamans B, van Tellingen O, Wesseling P, et al. (2008)
Magnetic resonance imaging-based detection of glial brain tumors in mice after
antiangiogenic treatment. Int J Cancer 122: 1981–1986.
8. Claes A, Wesseling P, Jeuken J, Maass C, Heerschap A, et al. (2008)
Antiangiogenic compounds interfere with chemotherapy of brain tumors due
to vessel normalization. Mol Cancer Ther 7: 71–78.
9. Navis AC, Hamans BC, Claes A, Heerschap A, Jeuken JW, et al. (2011) Effects
of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models.
J Pathol 223: 626–634.
10. Claes A, Schuuring J, Boots-Sprenger S, Hendriks-Cornelissen S, Dekkers M, et
al. (2008) Phenotypic and genotypic characterization of orthotopic human
glioma models and its relevance for the study of anti-glioma therapy. Brain
Pathol 18: 423–433.
11. Claes A, Leenders W (2008) Vessel normalization by VEGF inhibition. Cancer
Biol Ther 7: 7.
12. Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, et al. (2011) Anti-
VEGF treatment reduces blood supply and increases tumor cell invasion in
glioblastoma. Proc Natl Acad Sci U S A 108: 3749–3754.
13. Lamszus K, Kunkel P, Westphal M (2003) Invasion as limitation to anti-
angiogenic glioma therapy. Acta Neurochir Suppl 88: 169–177.
14. Leenders W, Kusters B, De Waal R (2002) Vessel co-option: How tumors obtain
blood supply in the absence of sprouting angiogenesis. Endothelium 9: 83–87.
15. Leenders WP, Kusters B, Verrijp K, Maass C, Wesseling P, et al. (2004)
Antiangiogenic therapy of cerebral melanoma metastases results in sustained
tumor progression via vessel co-option. Clin Cancer Res 10: 6222–6230.
16. Narayana A, Kelly P, Golfinos J, Parker E, Johnson G, et al. (2009)
Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma:
impact on local control and patient survival. J Neurosurg 110: 173–180.
17. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, et al. (2009)
Accelerated metastasis after short-term treatment with a potent inhibitor of
tumor angiogenesis. Cancer Cell 15: 232–239.
18. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, et al. (2009)
Antiangiogenic therapy elicits malignant progression of tumors to increased local
invasion and distant metastasis. Cancer Cell 15: 220–231.
19. Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, Williamson CW, et al.
(2012) Suppression of tumor invasion and metastasis by concurrent inhibition of
c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer
Discov 2: 270–287.
20. Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, et al. (2012)
VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a
MET/VEGFR2 Complex. Cancer Cell 22: 21–35.
21. Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, et al. (1994) A
multifunctional docking site mediates signaling and transformation by the
hepatocyte growth factor/scatter factor receptor family. Cell 77: 261–271.
22. Weidner KM, Di Cesare S, Sachs M, Brinkmann V, Behrens J, et al. (1996)
Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible
for epithelial morphogenesis. Nature 384: 173–176.
23. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell
144: 646–674.
24. (2008) Comprehensive genomic characterization defines human glioblastoma
genes and core pathways. Nature 455: 1061–1068.
25. Koochekpour S, Jeffers M, Rulong S, Taylor G, Klineberg E, et al. (1997) Met
and hepatocyte growth factor/scatter factor expression in human gliomas.
Cancer Res 57: 5391–5398.
26. Brockmann MA, Ulbricht U, Gruner K, Fillbrandt R, Westphal M, et al. (2003)
Glioblastoma and cerebral microvascular endothelial cell migration in response
to tumor-associated growth factors. Neurosurgery 52: 1391–1399; discussion
1399.
27. Lamszus K, Schmidt NO, Jin L, Laterra J, Zagzag D, et al. (1998) Scatter factor
promotes motility of human glioma and neuromicrovascular endothelial cells.
Int J Cancer 75: 19–28.
28. You WK, Sennino B, Williamson CW, Falcon B, Hashizume H, et al. (2011)
VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet
cancer. Cancer Res 71: 4758–4768.
29. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, et al. (2011) Cabozantinib
(XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses
metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10: 2298–2308.
30. Caretti V, Zondervan I, Meijer DH, Idema S, Vos W, et al. (2011) Monitoring
of tumor growth and post-irradiation recurrence in a diffuse intrinsic pontine
glioma mouse model. Brain Pathol 21: 441–451.
31. Hof D, Raats JM, Pruijn GJ (2005) Apoptotic modifications affect the
autoreactivity of the U1 snRNP autoantigen. Autoimmun Rev 4: 380–388.
32. Liu W, Fu Y, Xu S, Ding F, Zhao G, et al. (2011) c-Met expression is associated
with time to recurrence in patients with glioblastoma multiforme. J Clin
Neurosci 18: 119–121.
33. Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, et al. (2011) Mosaic
amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer
Cell 20: 810–817.
34. Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, et al. (2001)
Inhibition of Glioma Angiogenesis and Growth in Vivo by Systemic Treatment
with a Monoclonal Antibody against Vascular Endothelial Growth Factor
Receptor-2. Cancer Res 61: 6624–6628.
35. Li Y, Li A, Glas M, Lal B, Ying M, et al. (2011) c-Met signaling induces a
reprogramming network and supports the glioblastoma stem-like phenotype.
Proc Natl Acad Sci U S A 108: 9951–9956.
36. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, et al.
(2010) Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. J Clin Oncol 28: 1963–1972.
37. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in
antiangiogenic therapy. Science 307: 58–62.
38. Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, et al. (2009)
Edema control by cediranib, a vascular endothelial growth factor receptor-
targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth
in mice. J Clin Oncol 27: 2542–2552.
Dual Targeting of Tumor Cells and Stroma in Glioma
PLOS ONE | www.plosone.org 9 March 2013 | Volume 8 | Issue 3 | e58262
